Developing Airglove V2 Technology for Peripheral Arterial Disease Healthcare (DATPADH)

开发用于外周动脉疾病医疗保健 (DATPADH) 的气手套 V2 技术

• 批准号: 10043747
• 金额: $ 5.84万
• 依托单位: GREEN CROSS MEDICO LIMITED
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10043747
• 关键词: Developing; Airglove; V2; Technology; Peripheral

**Public description**Green Cross Medico, based in Hamilton, Scotland, applied for a Fast Start Innovation grant from Innovate UK to assist with the development of its unique and patented Airglove technology for peripheral arterial disease (PAD). The company has spent over five years developing Airglove Arm, which delivers warm-air treatment to act as a thermo-vasodilator.The first generation use of Airglove was to improve Difficult Intravenous Access (DIVA) cannulation. In the UK alone, over 32M cannulations take place each year and nearly one third require more than one attempt. Airglove facilitates DIVA cannulation, taking just 3 minutes to dilate the vein for improved access and is used in many clinical areas such as oncology, haematology, apheresis, infusion, PET Scans, nuclear medicine, plasma exchange therapy and radiology with proven 87.5% 1st time cannulation success in trials."Airglove has helped out with some really difficult cases where we would sometimes have to move to central lines" Nurse/Practitioner at Addenbrooke's Hospital, CambridgeHaving worked closely with NHS Innovation South East we were approached by Professor Philip Stather to re-develop the technology for PAD. An awarded grant will assist the company to develop Airglove Leg for self-management home therapy of patients with PAD. 200M people globally suffer with PAD, which is caused by a build-up of fatty deposits their leg arteries. It can result in leg pain (intermittent claudication) and reduced mobility. Sometimes PAD can progress to critical limb ischaemia and, worst case scenario, leg amputation with a 20% mortality within 6 months of diagnosis.The IUK Fast Start grant will fund the development of a new generation of internationally-compatible Airglove device for the LEG use with battery pack, disposable gloves, positioning the device for UK/International use.Airglove LEG will improve patient outcomes and quality of life including their carers. It will also provide clinicians with an effective tool for the self-management home therapy of PAD if supervised exercise therapy (SET) is not available in their hospital trust or patients are not able to travel due to mobility.Airglove will reduce costs for the NHS and other healthcare payers plus help increase the flow-through of patients helping to tackle the NHS backlog as outlined in the Health Secretary £36billion investment of "New treatments and diagnostic and streamlined surgical methods believed to result in more patients being seen to quickly and safely". Airglove will also create additional manufacturing, exports and employment in the UK.

**公开描述**总部设在苏格兰汉密尔顿的绿十字医疗公司向Innovate UK申请了一项快速启动创新拨款，以帮助开发其治疗外周动脉疾病(PAD)的独特专利AirGlove技术。该公司花了五年多的时间开发AirGlove手臂，这种手臂提供温暖的空气治疗，充当热血管扩张剂。AirGlove的第一代用途是改善困难的静脉通路(DIVA)插管。仅在英国，每年就有超过3200万例插管，其中近三分之一需要不止一次。AirGlove可以帮助DIVA插管，只需3分钟就可以扩张静脉以改善通道，并被用于许多临床领域，如肿瘤学、血液学、采集术、输液、PET扫描、核医学、血浆交换治疗和放射学，在试验中证明第一次插管成功率为87.5%。“AirGlove帮助解决了一些非常困难的病例，有时我们不得不转移到中心线”，剑桥Addenbrooke医院的护士/医生与NHS Innovation东南密切合作，菲利普·斯塔瑟教授找到我们，重新开发PAD的技术。一笔授予的赠款将帮助该公司开发用于PAD患者自我管理家庭治疗的AirGlove腿。全球有2亿人患有PAD，这是由于腿部动脉脂肪堆积造成的。它会导致腿部疼痛(间歇性跛行)和行动不便。有时，PAD会发展为严重的肢体缺血，在最糟糕的情况下，诊断后6个月内会有20%的死亡率截肢。IUK Fast Start赠款将资助开发新一代国际兼容的气手套设备，用于腿部使用电池组、一次性手套，将设备定位为英国/国际使用。气手套腿部将改善患者的预后和生活质量，包括他们的照顾者。它还将为临床医生提供一种有效的工具，用于在他们的医院信任无法获得监督运动疗法(SET)或患者因行动不便而无法出行时，对PAD进行自我管理家庭治疗。AirGlove将降低NHS和其他医疗保健支付者的成本，并帮助增加患者的流动，帮助解决NHS的积压问题，正如卫生部长GB 360亿英镑的投资所概述的那样，“新的治疗方法和诊断和简化的手术方法据信会导致更多的患者快速安全地得到治疗”。Airglove还将在英国创造额外的制造业、出口和就业机会。